Barinthus Biotherapeutics Plc. Overview
Valuation check: BRNS's ROE is -78.78%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-78.78%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Barinthus Biotherapeutics Plc. (BRNS) currently reports a ROE of -78.78%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Barinthus Biotherapeutics Plc.'s ROE history and peer comparisons.
Barinthus Biotherapeutics Plc.'s ROE of -78.78% is lower than the Healthcare sector average of 29.39%. That is roughly 368.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Barinthus Biotherapeutics Plc.'s current -78.78% should be judged against Healthcare norms (sector average: 29.39%) and against BRNS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -78.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Barinthus Biotherapeutics Plc., and consider following BRNS for alerts when major investors trade the stock.
Barinthus Biotherapeutics Plc. is classified in the Healthcare sector. On ROE, it currently shows -78.78% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BRNS with unrelated industries.
